The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme

被引:4
|
作者
Olthof, E. M. G. [1 ,4 ]
Aitken, C. A. [1 ,2 ]
Siebers, A. G. [3 ]
van Kemenade, F. J. [2 ]
de Kok, I. M. C. M. [1 ]
机构
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Rotterdam, Netherlands
[3] Palga Dutch Nationwide Pathol Databank, Houten, Netherlands
[4] Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
关键词
cervical cancer screening; compliance; HPV; loss to follow-up; EUROPEAN GUIDELINES; QUALITY-ASSURANCE; CARE FAILURES; COLPOSCOPY;
D O I
10.1002/ijc.34902
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss to follow-up (LTFU) within cervical screening programmes can result in missed clinically relevant lesions, potentially reducing programme effectiveness. To examine the health impact of losing women during the screening process, we determined the proportion of women LTFU per step of the Dutch hrHPV-based screening programme. We then determined the probability of being LTFU by age, screening history and sampling method (self- or clinician-sampled) using logistic regression analysis. Finally, we estimated the number of missed CIN2+/3+ lesions per LTFU moment by using the CIN-risk in women compliant with follow-up. Data from the Dutch nationwide pathology databank (Palga) was used. Women eligible for screening in 2017 and 2018 were included (N = 840,428). For clinician collected (CC) samples, the highest proportion LTFU was found following 'referral advice for colposcopy' (5.5% after indirect referral; 3.8% after direct referral). For self-sampling, the highest proportions LTFU were found following the advice for repeat cytology (13.6%) and after referral advice for colposcopy (8.2% after indirect referral; 4.3% after direct referral). Self-sampling users and women with no screening history had a higher LTFU-risk (OR: 3.87, CI: 3.55-4.23; OR: 1.39, CI: 1.20-1.61) compared to women that used CC sampling and women that have been screened before, respectively. Of all women LTFU in 2017/18, the total number of potentially missed CIN2+ was 844 (21% of women LTFU). Most lesions were missed after 'direct referral for colposcopy' (N = 462, 11.5% of women LTFU). So, this indicates a gap between the screening programme and clinical care which requires further attention, by improving monitoring of patients after referral. Loss to follow-up within cervical cancer screening programmes can result in missed clinically relevant lesions, potentially reducing programme effectiveness. In a more sensitive HPV-based programme, the loss of effectiveness may be larger than in cytology-based programmes. This study in the Netherlands is the first to quantify loss to follow-up in an organised cervical cancer screening programme and calculate the potentially missed cervical lesions. Along the referral pathway of the Dutch cervical cancer screening programme, most clinically relevant lesions were missed after referral for colposcopy, indicating a gap between screening and clinical care. image
引用
收藏
页码:2132 / 2141
页数:10
相关论文
共 50 条
  • [1] Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience
    Veijalainen, Olga
    Kares, Saara
    Kujala, Paula
    Vuento, Risto
    Osuala, Veronika
    Tirkkonen, Mika
    Luukkaala, Tiina
    Kholova, Ivana
    Maenpaa, Johanna
    CYTOPATHOLOGY, 2019, 30 (02) : 150 - 156
  • [2] HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme
    Polman, N. J.
    Snijders, P. J. F.
    Kenter, G. G.
    Berkhof, J.
    Meijer, C. J. L. M.
    PREVENTIVE MEDICINE, 2019, 119 : 108 - 117
  • [3] Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials
    Ronco, Guglielmo
    Dillner, Joakim
    Elfstrom, K. Miriam
    Tunesi, Sara
    Snijders, Peter J. F.
    Arbyn, Marc
    Kitchener, Henry
    Segnan, Nereo
    Gilham, Clare
    Giorgi-Rossi, Paolo
    Berkhof, Johannes
    Peto, Julian
    Meijer, Chris J. L. M.
    LANCET, 2014, 383 (9916): : 524 - 532
  • [4] Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic
    Olthof, E. M. G.
    Aitken, C. A.
    Siebers, A. G.
    van Kemenade, F. J.
    de Kok, I. M. C. M.
    PUBLIC HEALTH, 2024, 227 : 42 - 48
  • [5] HPV-based screening for prevention of invasive cervical cancer
    Sideri, Mario
    Igidbashian, Sarah
    LANCET, 2014, 383 (9925): : 1294 - 1294
  • [6] HPV-based cervical-cancer screening in China
    Arbyn, Marc
    Walker, Amy
    Meijer, Chris J. L. M.
    LANCET ONCOLOGY, 2010, 11 (12): : 1112 - 1113
  • [8] HPV-Based cervical screening in Portugal
    Pinto
    Sousa, R.
    Raposo, S.
    Sa, L.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2022, 270 : E76 - E76
  • [9] HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease
    Patricia Luhn
    Nicolas Wentzensen
    Current Obstetrics and Gynecology Reports, 2013, 2 (2) : 76 - 85
  • [10] HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease
    Luhn, Patricia
    Wentzensen, Nicolas
    CURRENT OBSTETRICS AND GYNECOLOGY REPORTS, 2013, 2 (02): : 76 - 85